Sourasky Medical Center (Ichilov)
Sourasky Medical Center (Ichilov)
Izrael, Tel Awiw
Nadir Arber
44 lat doświadczenia
akredytacje :
Akredytacje :
Therapy in Israel typically costs between $100 and $28,000. The total expense depends on whether you choose private practitioners or subsidized public healthcare, session frequency, and specialized clinical needs. Many international patients find that private medical costs in Israel offer approximately 20-30% savings compared to similar high-level care in the US.
Typical Therapy Costs in Israel
Most therapeutic and psychiatric services are concentrated in major hubs like Tel Aviv, Jerusalem, and Haifa. While private clinics in Tel Aviv may have higher demand, Jerusalem often provides competitive rates for specialized care. Consulting with a specialist can help clarify the final cost for your specific needs.
| Izrael | Turcja | Austria | |
| Szczepienie | od $100 | od $50 | od $50 |
| Ozonoterapia | od $300 | od $117 | od $200 |
| Infuzja krwi pępowinowej od dawcy | od $14,500 | od $5,000 | od $7,500 |
| Dożylnia terapia witaminą C | od $200 | od $150 | od $250 |
| Terapia witaminowa dożylna | - | od $150 | od $250 |
Państwo nie płacą za usługi Bookimed. Ceny leczenia terapii na stronie odpowiadają cennikowi kliniki. Płatność dokonywana jest bezpośrednio w klinice po przyjeździe. Dostępna jest płatność w ratach.
Bookimed dba o Państwa bezpieczeństwo. Współpracujemy tylko z klinikami spełniającymi wysokie międzynarodowe standardy w przeprowadzaniu terapii. Posiadają one wymagane licencje do obsługi pacjentów międzynarodowych na całym świecie.
Bookimed oferuje bezpłatną pomoc i wsparcie. Osobisty koordynator medyczny pozostaje w kontakcie przed, w trakcie i po podróży. Przy przechodzeniu procedur w terapii zawsze można liczyć na nasze wsparcie.
Prof. Nadir Arber kieruje Centrum Profilaktyki Raka w Centrum Medycznym Sourasky, posiadając ponad 30-letnie doświadczenie w zakresie nowotworów układu pokarmowego.
Prof. Amos Toren, MD, PhD, MHA, is a pediatric hemato-oncologist and BMT specialist. He served as Director of Pediatric Hemato-Oncology and BMT at Sheba Medical Center.
He is board certified in Pediatrics, Pediatric Hemato-Oncology, and Bone Marrow Transplantation. He holds a PhD in Human Genetics. He was Head of the Hematology Division at Tel Aviv University for two terms. He is a member of ASH, COG, ESPHI, EBMT, and CIBMTR. He also serves on the Ministry of Health Cord Blood Committee.
He led one of Israel’s most advanced pediatric oncology and BMT programs. The program treated children and young adults. His focus includes leukemia and lymphoma, immunodeficiencies, and rare cancers. He specializes in BMT and CAR T-cell therapy.
His translational research covers CAR T cells, cytokine-induced killer cells, pediatric brain tumors, and targeted therapies. He has worked with St. Anna, the NIH, and St. Jude. His publications include studies on pediatric SCT prophylaxis and PARP resistance.
Dr. Einat Shacham‑Shmueli is a senior medical oncologist at the Gastrointestinal Clinic, Cancer Center, Sheba Medical Center. She treats cancers of the colon, stomach, and pancreas. She also manages metastatic disease. She uses precision diagnostics and biomarkers, systemic therapies, and radiotherapy. Care is provided within a multidisciplinary team.
She has authored more than 25 peer‑reviewed papers on GI oncology, tumor biology, and new treatments. Her work includes studies on stenting for malignant colonic obstruction. She serves as an investigator in international programs, including the NCI, the Radiation Therapy Oncology Group, and the Cancer Therapy Evaluation Program.
Education: MD, Tel Aviv University. Oncology residency, Tel Aviv Sourasky Medical Center. Advanced training in GI oncology, UCSF. Accreditations: Board certified in Oncology and Gastroenterology. Member, Israel Society of Oncology and Radiotherapy.
Prof. Amit Tirosh is a senior endocrinologist and Head of the Neuroendocrine Tumors Service at Sheba Medical Center. He specializes in neuroendocrine tumors (NETs).
His work centers on hereditary NET syndromes. He is affiliated with the NIH in MEN1 research. He serves on an international VHL expert panel and helped write VHL management guidelines. He is the primary contact at Sheba’s multidisciplinary VHL clinic.
He leads the Endocrine Oncology Bioinformatics Lab. He collaborates with international teams, including the Weizmann Institute. He provides advanced NET care, including PRRT.
He earned his MD from the Hebrew University–Hadassah. He completed a residency at Assaf HaRofeh, an endocrinology fellowship at Rabin, and training at the NIH. He is board-certified in Endocrinology. He is a member of the Israeli Society of Endocrinology, the Endocrine Society, and the European Neuroendocrine Tumor Society. He has authored over 40 peer-reviewed papers, including in JAMA, Gastroenterology, and Radiology.